Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
23 Febrero 2024 - 3:05PM
Business Wire
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the
“Company”) today announced that it has granted stock options and
restricted stock units (“RSUs”) to Linda Arsenault, the Company’s
newly appointed Chief Human Resources Officer. The Compensation
Committee of Amylyx’ Board of Directors approved the grant,
effective February 20, 2024, to Ms. Arsenault of non-qualified
stock option awards to purchase up to 101,400 shares of the
Company’s common stock and 67,600 RSUs under the Amylyx
Pharmaceuticals, Inc. 2023 Inducement Plan (“2023 Inducement
Plan”). The awards were granted as an inducement material to Ms.
Arsenault entering into employment with Amylyx in accordance with
Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $14.91 per share, which is
equal to the closing price of Amylyx' common stock as reported by
The Nasdaq Global Select Market on February 20, 2024. The options
have a ten-year term and will vest over four years, with 25%
vesting on the one-year anniversary of the applicable vesting
commencement date and the remaining 75% vesting in a series of 36
successive monthly installments thereafter, subject to Ms.
Arsenault’s continued employment with Amylyx on such vesting dates.
The RSUs will vest in four installments on the first four
anniversaries of the applicable vesting commencement date, subject
to Ms. Arsenault’s continued employment with Amylyx on such vesting
dates. The awards are subject to the terms and conditions of the
2023 Inducement Plan.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is committed to supporting and
creating more moments for the neurodegenerative disease community
through the discovery and development of innovative new treatments.
Amylyx is headquartered in Cambridge, Massachusetts and has
operations in Canada, EMEA, and Japan. For more information, visit
amylyx.com and follow us on LinkedIn and X, formerly known as
Twitter. For investors, please visit investors.amylyx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240223796636/en/
Media Amylyx Media Team (857) 799-7274
amylyxmediateam@amylyx.com
Investors Lindsey Allen Amylyx Pharmaceuticals, Inc.
(857) 320-6244 Investors@amylyx.com
Amylyx Pharmaceuticals (NASDAQ:AMLX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Amylyx Pharmaceuticals (NASDAQ:AMLX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024